Drug Trial Radar · NCT07024823
A Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Jun 9, 2025
Primary completion
Jan 29, 2027
Study completion Jan 29, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jun 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD), and the effect of multiple doses of AZD4248 on the PK of oral midazolam and metformin.
Conditions
- Chronic Kidney Disease
Interventions
AZD4248Drug
AZD4248 will be administered orally.
PlaceboDrug
Placebo will be administered orally.
AZD4248Drug
AZD4248 will be administered via IV infusion.
PlaceboDrug
Placebo will be administered via IV infusion.
MidazolamDrug
Midazolam will be administered orally.
MetforminDrug
Metformin will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 to Follow Up visit (Part A: up to 12 days; Part B and C: up to 19 days)
- Part D: Intra- and inter-participant variability of estimated glomerular filtration rate (eGFR) derived from home self-testing device measurementsTime frame: Day 1 to Day 169
- Part E: Area under concentration-time curve from time 0 to infinity (AUCinf) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
- Part E: Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
- Part E: Maximum observed drug concentration (Cmax) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
- Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
- Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
- Part E: Ratio of Test treatment (AZD4248 + midazolam) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248Time frame: Days 1-2, 4-5, 17 and 18
- Part E: Terminal elimination half-life (t½λz) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
- Part E: Terminal rate constant (λz) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
- Part E: Time to reach maximum observed concentration (tmax) for midazolamTime frame: Days 1-2, 4-5, 17 and 18
- Part E: AUCinf for metforminTime frame: Days 2-4, 6, and 7-16
- Part E: AUClast for metforminTime frame: Days 2-4, 6, and 7-16
- Part E: Cmax for metforminTime frame: Days 2-4, 6, and 7-16
- Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUCinf (RAUCinf) of AZD4248Time frame: Days 2-4, 6, and 7-16
- Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on AUClast (RAUClast) of AZD4248Time frame: Days 2-4, 6, and 7-16
- Part E: Ratio of Test treatment (AZD4248 + metformin) to Reference (AZD4248) based on Cmax (RCmax) of AZD4248Time frame: Days 2-4, 6, and 7-16
- Part E: Renal clearance (CLR) for metforminTime frame: Days 2-4, and 6-8
- Part E: t½λz for metforminTime frame: Days 2-4, 6, and 7-16
- Part E: λz for metforminTime frame: Days 2-4, 6, and 7-16
- Part E: tmax for metforminTime frame: Days 2-4, 6, and 7-16
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Glendale, California · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
Ann Arbor, Michigan · Active not recruiting
Research Site
Saint Paul, Minnesota · Recruiting
Research Site
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.